Results 131 to 140 of about 13,617 (225)
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber +3 more
wiley +1 more source
Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 607-614, June 2026.ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman +9 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Hypokalemic periodic paralysis (hKPP) is a rare neuromuscular channelopathy characterized by transient episodes of muscle weakness or paralysis associated with low serum potassium levels. It has been most commonly linked to autosomal dominant mutations in ion channel genes, specifically CACNA1S and SCN4A, which impair skeletal muscle ...
Ali Moradi +8 more
wiley +1 more source
Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Health Science Reports, Volume 9, Issue 6, June 2026.ABSTRACT Background and Aims Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy.
Sanila Mughal +7 more
wiley +1 more source
OMALIZUMAB IN TREATMENT FOR ALLERGIES
, 2007 Omalizumab, whose active basis is recombinant, human, monoclonal antibodies to Ige, gives a unique therapeutic field in treatment for allergies. The present medication constitutes neutralizing antibodies, connecting Ige even before any appearance of ...
T.V. Kulichenko
core
Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade +5 more
wiley +1 more source
Omalizumab for severe persistent allergic asthma
, 2009 This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of omalizumab for the treatment of chronic severe persistent allergic asthma, in accordance with the licensed indication, based
Hartwell, D. +13 more
core +1 more source
OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION
Педиатрическая фармакология, 2007 Antibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the ...
T.V. Kulichenko
doaj +2 more sources
Omalizumab: Anti-IgE untuk Terapi Asma
, 2013 Injeksi omalizumab digunakan secara terbatas hanya untuk pasien yang asmanya tidak terkontrol dengan inhalasi kortikosteroid dan nilai pemeriksaan antibodi IgEnya >30 IU/mL (step 5).
Herawati, Fauna
core
Clinical &Experimental Allergy, Volume 56, Issue 6, Page 629-638, June 2026.Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan +13 more
wiley +1 more source